⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL27447529 | 0.84 | — | — | |
| SCHEMBL7844 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL27667996 | 0.81 | — | — | |
| SCHEMBL10582117 | 0.81 | — | — | |
| SCHEMBL6822696 | 0.81 | — | — | |
| SCHEMBL11462035 | 0.81 | — | — | |
| SCHEMBL4443334 | 0.81 | — | — | |
| SCHEMBL28257098 | 0.81 | — | — | |
| Ethyne SCHEMBL28097770 | 0.78 | — | — | |
| SCHEMBL6398945 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100390154-C | Quinoline and quinoxaline compounds as PDGF-receptor and/or LCK tyrosine kinase inhibitors | AVENTIS PHARM PROD INC (GB) | 2008-05-28 | — | — | CN | claimed |
| CN-100357276-C | Quinoline and quinoxaline compounds as PDGF-R and/or LCD tyrosine kinase inhibitors | AVENTIS PHARM PROD INC (US) | 2007-12-26 | — | — | CN | claimed |
| US-8569350-B2 | Anti-mitotic anti-proliferative compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-10-29 | — | — | US | disclosed |
| US-8455537-B2 | Estrogen receptor modulators and uses thereof | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120149744-A1 | ANTI-MITOTIC ANTI-PROLIFERATIVE COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143299-B2 | Anti-mitotic anti-proliferative compounds | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110319465-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2011-12-29 | — | — | US | disclosed |
| US-7989487-B2 | Estrogen receptor modulators and uses thereof | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100152271-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | UNIVERSIT OF MEDICINE AND DENISTRY OF NEW JERSEY (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090317440-A1 | ANTI-MITOTIC ANTI-PROLIFERATIVE COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2009-12-24 | — | — | US | disclosed |
| US-7550597-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1133481-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-R AND/OR LCK TYROSINE KINASE INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| EP-1133479-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| EP-1133480-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-RECEPTOR AND/OR LCK TYROSINE KINASE INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6245760-B1 | ANTICANCER AGENTS; ANTIINFLAMMATORYA GENTS; SKIN DISORDERS | AVENTIS PHARMACEUTICALS PRODUCTS, INC | 2001-06-12 | — | — | US | disclosed |
| US-6180632-B1 | USE OF THESE COMPOUNDS FOR TREATING DISORDERS/CONDITIONS INVOLVING CELLULAR DIFFERENTIATION, PROLIFERATION, EXTRACELLULAR MATRIX PRODUCTION OR MEDIATOR RELEASE AND/OR T CELL ACTIVATION AND PROLIFERATION | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-01-30 | — | — | US | disclosed |
| US-6159978-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCT, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000031051-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-RECEPTOR AND/OR LCK TYROSINE KINASE INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031049-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-R AND/OR LCK TYROSINE KINASE INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031050-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | disclosed |